Telmisartan and Hydrochlorothiazide Tablets USP — Class II drug recall D-1306-2022
Terminated recall by Glenmark Pharmaceuticals Inc., USA, reported 2022-08-17, distributed nationwide. Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister
| Recall number | D-1306-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States |
| Recall initiated | 2022-06-29 |
| Classified | 2022-08-05 |
| Reported by FDA | 2022-08-17 |
| Terminated | 2024-06-27 |
| Distributed | Nationwide (US) |
| Reason classes | packaging |
| NDC | 68462-0840, 68462-0840-13, 68462-0841, 68462-0841-13, 68462-0842, 68462-0842-13 |
| Lot numbers | 17210929, 17210930, 17211203, 17211643, 17211646, 17211649 |
| Expiration dates | 2023-05, 2023-06, 2023-08 |
Product
Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc,m USA, Mahwah, NJ 07430, NDC 68462-841-13.
Reason for recall
Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1306-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.